C12N 2810/858
From apolipopeptides
Official title: from apolipopeptides
C12N2810/858 (From apolipopeptides) appears on 6 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 7
- Assignees
- 4
- Inventors
- 14
- Latest grant
- 12 Aug 2014
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 2 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 3 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
By publication year.
Recent patents
- Raav expression systems for genetic modification of specific capsid proteins12 Aug 2014US 8,802,080 B2University of Florida Research Foundation, Inc.
- Compositions and methods for polynucleotide delivery9 Dec 2008US 7,462,592 B2Novartis Vaccines and Diagnostics, Inc.
- Non-invasive gene targeting to ocular cells15 Aug 2006US 7,090,864 B2The Regents of the University of California
- Compositions and methods for polynucleotide delivery22 Oct 2002US 6,468,986 B1Chiron Corporation
- Non-invasive gene targeting to the brain16 Apr 2002US 6,372,250 B1The Regents of the University of California
- Methods of gene delivery using capsid-modified raav expression systems1 Jan 2015US 2015/0005369 A1University of Florida Research Foundation, Inc.
- Compositions and methods for polynucleotide delivery17 Apr 2008US 2008/0089938 A9Novartis Vaccines and Diagnostics, Inc.
- Improved rAAv vectors28 Dec 2006US 2006/0292117 A1
- Non-invasive gene targeting to ocular cells18 May 2006US 2006/0105982 A1The Regents of the University of California
- Raav expression systems for genetic modification of specific capsid proteins27 Apr 2006US 2006/0088936 A1University of Florida Research Foundation, Inc.
Most cited
By later US patents
- Non-invasive gene targeting to the brain83US 6,372,250 B1The Regents of the University of California · 2002
- Compositions and methods for polynucleotide delivery21US 6,468,986 B1Chiron Corporation · 2002
- Non-invasive gene targeting to ocular cells17US 7,090,864 B2The Regents of the University of California · 2006
- Polycationic polymers16US 6,251,433 B1Chiron Corporation · 2001
- Raav expression systems for genetic modification of specific capsid proteins9US 8,802,080 B2University of Florida Research Foundation, Inc. · 2014